Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $164.00.

Several equities research analysts have recently commented on ILMN shares. Robert W. Baird boosted their price objective on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a report on Wednesday, August 28th. UBS Group boosted their price objective on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Stephens boosted their price objective on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Finally, Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a report on Thursday, October 17th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Freemont Management S.A. purchased a new position in shares of Illumina during the 3rd quarter valued at $1,565,000. Cetera Advisors LLC purchased a new position in shares of Illumina during the 1st quarter valued at $610,000. Weybosset Research & Management LLC lifted its position in shares of Illumina by 92.0% during the 3rd quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock valued at $2,354,000 after buying an additional 8,650 shares during the last quarter. B. Riley Wealth Advisors Inc. lifted its position in shares of Illumina by 176.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after buying an additional 4,579 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Illumina by 3.6% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock valued at $41,748,000 after buying an additional 13,725 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $144.15 on Friday. The business has a fifty day moving average of $141.88 and a 200-day moving average of $125.95. Illumina has a twelve month low of $99.23 and a twelve month high of $156.66. The firm has a market cap of $22.86 billion, a PE ratio of -14.47 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter last year, the firm posted $0.33 earnings per share. The firm’s revenue was down 3.5% on a year-over-year basis. On average, equities research analysts predict that Illumina will post 4.11 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.